Roivant Sciences Ltd (ROIV) concluded trading on Wednesday at a closing price of $10.39, with 4.64 million shares of worth about $48.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.78% during that period and on Wednesday February 7 the price saw a gain of about 0.87%. Currently the company’s common shares owned by public are about 760.14M shares, out of which, 478.44M shares are available for trading.
Stock saw a price change of 3.90% in past 5 days and over the past one month there was a price change of -9.18%. Year-to-date (YTD), ROIV shares are showing a performance of -7.48% which increased to 35.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.59 but also hit the highest price of $13.24 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 5.32 million. The stock is currently trading -1.02% below its 20-day simple moving average (SMA20), while that difference is down -0.69% for SMA50 and it goes to 1.59% higher than SMA200.
Roivant Sciences Ltd (NASDAQ: ROIV) currently have 760.14M outstanding shares and institutions hold larger chunk of about 56.50% of that.
The stock has a current market capitalization of $8.35B and its 3Y-monthly beta is at 1.34. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 5.82 while making debt-to-equity ratio of 0.53. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 3.34% while standing at 3.50% over the month.
Analysts are in expectations that Roivant Sciences Ltd (ROIV) stock would likely to be making an EPS of -$0.32 in the current quarter, while forecast for next quarter EPS is -$0.31 and it is -$1.12 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.38 which is -$0.26 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.49 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -12.52% while it is estimated to increase by 15.64% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on January 05, 2024 offering an Overweight rating for the stock and assigned a target price of $20 to it.
